Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
复制标题
DOI：
10.1001/jama.297.5.499
复制
发表时间：
2007-02-07
影响因子：
120.7
通讯作者：
Nissen, Steven E.
中科院分区：
文献类型：
--
作者：
Nicholls, Stephen J.;Tuzcu, E. Murat;Nissen, Steven E.
他汀类药物可降低低密度脂蛋白胆固醇（LDL-C）水平，减缓冠状动脉粥样硬化的进展。然而，目前尚无他汀类药物引起的高密度脂蛋白胆固醇（HDL-C）变化与疾病进展之间的关系的数据。目的探讨LDL-C和HDL-C水平变化与动脉粥样硬化负荷的关系。设计、设置和患者事后分析结合4项前瞻性随机试验的原始数据（1999年至2005年在美国、北美、欧洲和澳大利亚演出），其中1455例冠状动脉造影患者在接受他汀类药物治疗18个月或24个月的同时接受了连续的血管内超声检查。所有研究均在同一核心实验室进行超声分析。主要结果测量脂蛋白水平变化与冠状动脉粥样硬化体积之间的关系。平均（SD）LDL-C水平从124.0（38.3）mg/dL（3.2 [0.99] mmol/L）降至87.5（28.8）mg/dL（2.3 [0.75] mmol/L）（降低23.5%; P
Context Statins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow progression of coronary atherosclerosis. However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression.Objective To investigate the relationship between changes in LDL-C and HDL-C levels and atheroma burden.Design, Setting, and Patients Post-hoc analysis combining raw data from 4 prospective randomized trials ( performed in the United States, North America, Europe, and Australia between 1999 and 2005), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrasonography while receiving statin treatment for 18 months or for 24 months. Ultrasound analysis was performed in the same core laboratory for all of the studies.Main Outcome Measure Relationship between changes in lipoprotein levels and coronary artery atheroma volume.Results During statin therapy, mean (SD) LDL-C levels were reduced from 124.0 (38.3) mg/dL (3.2 [0.99] mmol/L) to 87.5 (28.8) mg/dL (2.3 [0.75] mmol/L) (a 23.5% decrease; P